Myovant Sciences Ltd (MYOV)

$26.98 0.00 (0.00%)

19:00 EST MYOV Stock Quote Delayed 30 Minutes

MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences

By David Moadel, InvestorPlace Contributor Oct 24, 2022

Acquisition announcements can cause explosive share-price moves, and MYOV stock is spiking in the wake of a big-dollar buyout announcement.

Why Is Myovant Sciences (MYOV) Stock Up 30% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

3 Biotech Stocks Ready for Big Breakthroughs Like Biogen

More Articles

Volume:

Previous Close -

Market Cap 2.48B

PE Ratio -14.13

EPS -1.91

Volume (Avg. Vol.)

Day's Range -

52-Week Range -

Dividend & Yield N/A (N/A)

MYOV Stock Predictions, Articles, and Myovant Sciences Ltd News

From InvestorPlace
From the Web

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M (NYSE:MYOV)

From Seeking Alpha Jan 26, 2023

Myovant Sciences press release (MYOV): Q3 GAAP EPS of -$0.56 beats by $0.08.Revenue of $100.23M (+84.1% Y/Y) misses by $2.13M.Cash, cash equivalents, marketable securities, and...

Myovant (MYOV) Stock Rising on Acquisition News

From TipRanks Oct 24, 2022

Myovant Sciences Ltd. (MYOV) has risen more than 8% in pre-market trading, thanks to the news about its acquisition by Sumitomo Unit. Sumitomo, a subsidiary of Sumi...

Sumitomo Unit Agrees to Buy Myovant After Increasing Offer

From Bloomberg Oct 24, 2022

A fully-owned subsidiary of Sumitomo Pharma Co. agreed to buy the rest of drugmaker Myovant Sciences Ltd. for $1.7 billion after raising its offer, as it seeks to bolster the development of medicines for women’s health and prostate cancer.

Myovant Sciences Rejects Sumitovant’s $2.4 Billion Acquisition Offer

From TipRanks Oct 3, 2022

Myovant Sciences (NYSE: MYOV) clarified on Sunday that it was rejecting the preliminary, non-binding offer from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co. Su...

Sumitomo Offers to Buy All of Myovant in Deal Worth $2.5 Billion

From Bloomberg Oct 3, 2022

A fully-owned subsidiary of Sumitomo Pharma Co. offered to buy the remaining outstanding shares of pharmaceutical company Myovant Sciences Ltd., seeking to bolster the development of drugs for women’s health and prostate cancer.

Myovant Sciences (MYOV) Receives a Buy from Robert W. Baird

From TipRanks Aug 11, 2022

In a report released on August 9, Brian Skorney from Robert W. Baird maintained a Buy rating on Myovant Sciences (MYOV – Research Report), with a price target...

ADVERTISEMENT